Iradimed (NASDAQ:IRMD) Issues Q1 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.390-0.430 for the period, compared to the consensus estimate of 0.410. The company issued revenue guidance of $19.2 million-$19.4 million, compared to the consensus revenue estimate of $19.1 million. Iradimed also updated its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Trading Down 10.2 %

Shares of Iradimed stock traded down $6.16 on Thursday, hitting $54.32. 41,046 shares of the company traded hands, compared to its average volume of 39,609. Iradimed has a 52 week low of $40.18 and a 52 week high of $63.29. The company has a market cap of $688.23 million, a PE ratio of 37.13 and a beta of 0.82. The stock’s 50 day moving average price is $57.16 and its 200-day moving average price is $52.02.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.05). Iradimed had a return on equity of 23.99% and a net margin of 26.12%. As a group, research analysts anticipate that Iradimed will post 1.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Insider Buying and Selling at Iradimed

In related news, CFO John Glenn sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This trade represents a 36.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 37.10% of the company’s stock.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.